Basic Information
RNALocate ID: | RLID:11001007 |
RNA Symbol: | hsa-miR-101-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-101-3p |
RNA ID: | miRBase:MIMAT0000099 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 25349172 |
Tissue/Cell Line: | Serum |
Method: | Next-generation RNA sequencing |
Originally published in Mol Psychiatry. Cheng L, et al, 2015. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Deep sequencing of the exosomal RNA extracted from serum samples was performed and sequences were mapped to miRBase Exosomal miRNA biomarkers for Alzheimer's disease. Approximately half of the reads obtained (43%) from small RNA sequencing corresponded with miRNA sequences (Supplementary Table 1). Overall, the sample cohort mapped to 1419 known human miRNA sequences (Supplementary Table 2). Following normalisation of reads and performing ANOVA analyses, 17 miRNA were found to be significantly deregulated (Figure 1); 14 miRNA were found to be upregulated (hsa-miR-361-5p, hsa-miR-30e-5p, hsa-miR-93-5p, hsa-miR-15a-5p, hsa-miR-143-3p, hsa-miR-335-5p, hsa-miR-106b-5p, hsa-miR-101-3p, hsa-miR-424-5p, hsa-miR-106a-5p, hsa-miR-18b-5p, hsa-miR-3065-5p, hsa-miR-20a-5p and hsa-miR-582-5p) and three miRNA were found to be downregulated (hsa-miR-1306-5p, hsa-miR-342-3p and 15b-3p; Table 2). Data are collected from Table 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001436 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001437 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001438 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001439 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001440 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001441 | Nucleus | GC cell line (MGC-803) | 29872807 |
RLID:01001442 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001003 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001004 | Exosome | Renal cancer cells | 21670082 |
RLID:11001005 | Exosome | Plasma | 23663360 |
RLID:11001006 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001008 | Microvesicle | Plasma | 23077538 |
RLID-D:11000033 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
RLID-D:11000298 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-101-3p | Diffuse large b cell lymphoma | MNDR-E-MI-02632 |
MNDR | hsa-miR-101-3p | Rheumatic heart diseases | MNDR-E-MI-02633 |
MNDR | hsa-miR-101-3p | Large cell neuroendocrine cancer | MNDR-E-MI-02634 |
MNDR | hsa-miR-101-3p | Medulloblastoma | MNDR-E-MI-02635 |
MNDR | hsa-miR-101-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-02636 |
MNDR | hsa-miR-101-3p | Ovarian clear cell carcinoma | MNDR-E-MI-02637 |
MNDR | hsa-miR-101-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-02638 |
MNDR | hsa-miR-101-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-02639 |
MNDR | hsa-miR-101-3p | Lymphoma | MNDR-E-MI-02640 |
MNDR | hsa-miR-101-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-02641 |
MNDR | hsa-miR-101-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-02642 |
MNDR | hsa-miR-101-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-02643 |
MNDR | hsa-miR-101-3p | Her2-receptor positive breast cancer | MNDR-E-MI-02644 |
MNDR | hsa-miR-101-3p | Triple negative breast cancer | MNDR-E-MI-02645 |
MNDR | hsa-miR-101-3p | Childhood acute lymphoblastic leukemia | MNDR-E-MI-02646 |
MNDR | hsa-miR-101-3p | Dermatomyositis | MNDR-E-MI-02647 |
MNDR | hsa-miR-101-3p | Prostate cancer | MNDR-E-MI-02648 |
MNDR | hsa-miR-101-3p | Chronic lymphocytic leukemia | MNDR-E-MI-02649 |
MNDR | hsa-miR-101-3p | Gastric cancer | MNDR-E-MI-02650 |
MNDR | hsa-miR-101-3p | Gastric lymphoma | MNDR-E-MI-02651 |
MNDR | hsa-miR-101-3p | Alzheimer disease | MNDR-E-MI-02652 |
MNDR | hsa-miR-101-3p | Attention deficit hyperactivity disorder | MNDR-E-MI-02653 |
MNDR | hsa-miR-101-3p | Intracranial aneurysm | MNDR-E-MI-02654 |
MNDR | hsa-miR-101-3p | Urinary bladder cancer | MNDR-E-MI-02655 |
MNDR | hsa-miR-101-3p | Esophageal carcinoma | MNDR-E-MI-02656 |
MNDR | hsa-miR-101-3p | Heart disease | MNDR-E-MI-02657 |
MNDR | hsa-miR-101-3p | Dysautonomia familial | MNDR-E-MI-02658 |
MNDR | hsa-miR-101-3p | Duchenne muscular dystrophy | MNDR-E-MI-02659 |
MNDR | hsa-miR-101-3p | Graves disease | MNDR-E-MI-02660 |
MNDR | hsa-miR-101-3p | Malaria | MNDR-E-MI-02661 |
MNDR | hsa-miR-101-3p | Leukemia | MNDR-E-MI-02662 |
MNDR | hsa-miR-101-3p | Huntington disease | MNDR-E-MI-02663 |
MNDR | hsa-miR-101-3p | Chorea | MNDR-E-MI-02664 |
MNDR | hsa-miR-101-3p | Cardiovascular disease | MNDR-E-MI-02665 |
MNDR | hsa-miR-101-3p | Moyamoya disease | MNDR-E-MI-02666 |
MNDR | hsa-miR-101-3p | Lung cancer | MNDR-E-MI-02667 |
MNDR | hsa-miR-101-3p | Down syndrome | MNDR-E-MI-02668 |
MNDR | hsa-miR-101-3p | Parkinson disease | MNDR-E-MI-02669 |
MNDR | hsa-miR-101-3p | Breast cancer | MNDR-E-MI-02670 |
MNDR | hsa-miR-101-3p | Cancer | MNDR-E-MI-02671 |
MNDR | hsa-miR-101-3p | Squamous cell carcinoma | MNDR-E-MI-02672 |
MNDR | hsa-miR-101-3p | Pancreatic cancer | MNDR-E-MI-02673 |
MNDR | hsa-miR-101-3p | Melanoma | MNDR-E-MI-02674 |
MNDR | hsa-miR-101-3p | Rectum adenocarcinoma | MNDR-E-MI-02675 |
MNDR | hsa-miR-101-3p | Hepatitis B | MNDR-E-MI-02676 |
MNDR | hsa-miR-101-3p | Epithelial ovarian cancer | MNDR-E-MI-02677 |
MNDR | hsa-miR-101-3p | Nephroblastoma | MNDR-E-MI-02678 |
MNDR | hsa-miR-101-3p | Colon cancer | MNDR-E-MI-02679 |
MNDR | hsa-miR-101-3p | Colon adenocarcinoma | MNDR-E-MI-02680 |
MNDR | hsa-miR-101-3p | Familial ovarian cancer | MNDR-E-MI-02681 |
MNDR | hsa-miR-101-3p | Prostate adenocarcinoma | MNDR-E-MI-02682 |
MNDR | hsa-miR-101-3p | Kidney cancer | MNDR-E-MI-02683 |
MNDR | hsa-miR-101-3p | Thyroid adenomas | MNDR-E-MI-02684 |
MNDR | hsa-miR-101-3p | Carcinoma ductal breast | MNDR-E-MI-02685 |
MNDR | hsa-miR-101-3p | Glioblastoma | MNDR-E-MI-02686 |
MNDR | hsa-miR-101-3p | Astrocytoma | MNDR-E-MI-02687 |
MNDR | hsa-miR-101-3p | Glioma | MNDR-E-MI-02688 |
MNDR | hsa-miR-101-3p | Gallbladder cancer | MNDR-E-MI-02689 |
MNDR | hsa-miR-101-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-02690 |
MNDR | hsa-miR-101-3p | Osteosarcoma | MNDR-E-MI-02691 |
MNDR | hsa-miR-101-3p | Liposarcoma | MNDR-E-MI-02692 |
MNDR | hsa-miR-101-3p | Inclusion body myositis | MNDR-E-MI-02693 |
MNDR | hsa-miR-101-3p | Meningioma | MNDR-E-MI-02694 |
MNDR | hsa-miR-101-3p | Liver cancer | MNDR-E-MI-02695 |
MNDR | hsa-miR-101-3p | Gastric adenocarcinoma | MNDR-E-MI-02696 |
MNDR | hsa-miR-101-3p | Cervical squamous cell carcinoma | MNDR-E-MI-02697 |
MNDR | hsa-miR-101-3p | Lung squamous cell carcinoma | MNDR-E-MI-02698 |
MNDR | hsa-miR-101-3p | Non small cell lung carcinoma | MNDR-E-MI-02699 |
MNDR | hsa-miR-101-3p | Lung adenocarcinoma | MNDR-E-MI-02700 |
MNDR | hsa-miR-101-3p | Adrenocortical cancer | MNDR-E-MI-02701 |
MNDR | hsa-miR-101-3p | Bladder urothelial carcinoma | MNDR-E-MI-02702 |
MNDR | hsa-miR-101-3p | Kidney renal clear cell carcinoma | MNDR-E-MI-02703 |
MNDR | hsa-miR-101-3p | Renal clear cell carcinoma | MNDR-E-MI-02704 |
MNDR | hsa-miR-101-3p | Allergic rhinitis | MNDR-E-MI-02705 |
MNDR | hsa-miR-101-3p | Large cell carcinoma | MNDR-E-MI-02706 |
MNDR | hsa-miR-101-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-02707 |
MNDR | hsa-miR-101-3p | Cholangiocarcinoma | MNDR-E-MI-02708 |
MNDR | hsa-miR-101-3p | Esophageal cancer | MNDR-E-MI-02709 |
MNDR | hsa-miR-101-3p | Liver cirrhosis | MNDR-E-MI-02710 |
MNDR | hsa-miR-101-3p | Lung small cell carcinoma | MNDR-E-MI-02711 |
MNDR | hsa-miR-101-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-02712 |
MNDR | hsa-miR-101-3p | Testicular germ cell cancer | MNDR-E-MI-02713 |
MNDR | hsa-miR-101-3p | Bladder transitional cell carcinoma | MNDR-E-MI-02714 |
MNDR | hsa-miR-101-3p | Breast invasive carcinoma | MNDR-E-MI-02715 |
MNDR | hsa-miR-101-3p | Early hepatocellular carcinoma | MNDR-E-MI-02716 |
MNDR | hsa-miR-101-3p | Familiar ovarian carcinoma | MNDR-E-MI-02717 |
MNDR | hsa-miR-101-3p | B-cell lymphoma | MNDR-E-MI-02718 |
MNDR | hsa-miR-101-3p | Rheumatoid arthritis | MNDR-E-MI-02719 |
MNDR | hsa-miR-101-3p | T-cell leukemia | MNDR-E-MI-02720 |
MNDR | hsa-miR-101-3p | Malignant pleural mesothelioma | MNDR-E-MI-02721 |
MNDR | hsa-miR-101-3p | Retinoblastoma | MNDR-E-MI-02722 |
MNDR | hsa-miR-101-3p | Neuroblastoma | MNDR-E-MI-02723 |
MNDR | hsa-miR-101-3p | Chronic myeloid leukemia | MNDR-E-MI-02724 |
MNDR | hsa-miR-101-3p | Hodgkin lymphoma | MNDR-E-MI-02725 |
MNDR | hsa-miR-101-3p | Burkitt lymphoma | MNDR-E-MI-02726 |
MNDR | hsa-miR-101-3p | Crohn disease | MNDR-E-MI-02727 |
MNDR | hsa-miR-101-3p | Neuromyelitis optica | MNDR-E-MI-02728 |
MNDR | hsa-miR-101-3p | Skin cutaneous melanoma | MNDR-E-MI-02729 |
MNDR | hsa-miR-101-3p | Skin melanoma | MNDR-E-MI-02730 |
MNDR | hsa-miR-101-3p | Acute myeloid leukemia | MNDR-E-MI-02731 |
MNDR | hsa-miR-101-3p | Colon and rectal adenocarcinoma | MNDR-E-MI-02732 |
MNDR | hsa-miR-101-3p | Nasopharyngeal carcinoma | MNDR-E-MI-02733 |
MNDR | hsa-miR-101-3p | Ovarian epithelial cancer | MNDR-E-MI-02734 |
MNDR | hsa-miR-101-3p | Ependymoma | MNDR-E-MI-02735 |
MNDR | hsa-miR-101-3p | Nasopharyngeal cancer | MNDR-E-MI-02736 |
MNDR | hsa-miR-101-3p | Stroke lacunar | MNDR-E-MI-02737 |
MNDR | hsa-miR-101-3p | Breast cancer her3+ negative | MNDR-E-MI-02738 |
MNDR | hsa-miR-101-3p | High grade dysplastic nodule | MNDR-E-MI-02739 |
MNDR | hsa-miR-101-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-02740 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022076 |
TOP